Listed below are the current guidelines, provisional clinical opinions, endorsements, and updates in development. Topics prioritized for development by the Clinical Practice Guidelines Committee and Guideline Advisory Groups are listed by disease site. To submit a topic for consideration, take our survey. To learn more about the ASCO Guideline development process, access the Guideline Methodology page. If you are interested in guideline development, please visit the volunteer portal to express interest.

Guidelines in Development


  • Germline Testing in Patient with Breast Cancer: ASCO-SSO Guideline
  • Medical Therapy for Nonmetastatic HR+, HER2-negative Breast Cancer
  • Breast Cancer Follow-up and Management After Primary Treatment
  • Capivasertib in HR+, HER2-negative Advanced Breast Cancer (rapid update)
  • Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
  • CDK4/6 Inhibitors Plus Endocrine Therapy in Early Breast Cancer (rapid update) 
  • Postmastectomy Radiotherapy: ASTRO-ASCO-SSO Guideline Update


  • Symptom Management for Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors
  • Systemic Therapy for Locally Advanced Rectal Cancer
  • Systemic Therapy and Radiation Therapy for Stage I-III Anal Cancer (in partnership with AHRQ/PCORI)
  • Diagnostic Imaging and Systemic Therapy for Non-metastatic Gastric Cancer
  • Systemic Therapy for Advanced Hepatocellular Carcinoma (Update)


  • Genomic and Germline Testing Advanced and Metastatic Prostate Cancer 
  • Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer Update


  • Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer

Head and Neck

  • Consideration of dental care and osteonecrosis in patients treated with radiotherapy for head and neck cancer
  • Transoral Robotic Surgery for Oropharynx Cancer: Optimizing patient selection in HPV+ oropharyngeal cancer and use of adjuvant therapy


  • Treatment of Newly Diagnosed CLL Guideline 
  • Treatment of Multiple Myeloma Guideline Update 


  • Germline Genetic Testing
  • Use of cfDNA in Diagnosis and Monitoring in Solid Tumors and Lymphomas


Supportive Care


  • Management of Cancer During Pregnancy
  • ASCO/MASCC Practice Standards in Metastatic Cancer Survivorship
  • Screening, Assessment, and Management of Fatigue in Adult Survivors of Cancer Update
  • Fertility Preservation Update



Guideline Development Priorities 2023-2024

Breast Cancer

  • Disease Management for Patients with Advanced HER2–positive Breast Cancer and Brain Metastases
  • Use of Endocrine Therapy for Breast Cancer Risk Reduction
  • Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer
  • Transgender Breast Cancer Care

Gastrointestinal Cancer

  • Systemic Therapy for Advanced Biliary Tract Cancer
  • Immunotherapy and Targeted Therapy for Advanced Gastro/Esophageal Carcinoma
  • Locally Advanced Esophageal
  • Local and Regional Therapies, Including Adjuvant Therapy, for Locally Advanced HCC
  • Local and Regional Therapies for Biliary Tract Cancer

Genitourinary Cancer

  • Primary Tumor-Directed and Metastasis-Directed Local Therapy in metastatic Prostate Cancer
  • Special Considerations for Older Patients with Genitourinary Cancers
  • Genitourinary Cancers Survivorship
  • Adjuvant treatment of localized and oligometastatic RCC after definitive therapy

Gynecologic Cancer

  • First Platinum-Sensitive Ovarian Cancer Recurrence
  • Gynecologic Cancers Survivorship
  • Treatment of Invasive Cervical Cancer
  • Recurrent Endometrial Cancer

Head and Neck Cancer

  • Use of Systemic Treatment in the Management of Advanced Thyroid Cancer
  • Management of Advanced Cutaneous Squamous Cell of the Head and Neck
  • Management of Head and Neck Cancers in Older Adults (80+) and/or Frail Patient Population
  • Management of Locoregionally Recurrent Head and Neck Cancer
  • Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer

Hematological Malignancies

  • Management of Side Effects from Immune Effector Cell Therapy
    • Update of Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor (CAR) T-Cell Therapy AND Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy 
  • Treatment of Relapsed/Refractory Aggressive Lymphomas
  • Risk-Based Management of Myelodysplastic Syndromes


  • Systemic Therapy for Sarcoma
  • Treatment of Leptomeningeal Metastases
  • Treatment of Non-Melanoma Skin Cancer

Resource Stratified

  • Geriatric Oncology
  • Survivorship Care in Adolescents, Young Adults, and Adults
  • Treatment of Patients with Endometrial Cancer

Supportive Care

  • Integration/Implementation of Patient-Reported Outcomes in Cancer Care
  • Cancer and Treatment Related Cognitive Impairment
  • Addressing the Needs of Informal Caregivers of People Living with Cancer

Patient & Survivor Care

  • Young Adult Survivorship Guideline for Ages 21-39
  • Management of Sleep Problems in Cancer Survivors
  • Survivorship After Stem Cell Transplantation
  • Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers Update

Thoracic Cancer

  • Management of Stage I Non-Small Cell Lung Cancer
  • Molecular Testing for the Selection of Patients with Lung Cancer for Treatment with Targeted Tyrosine Kinase Inhibitors Guideline Endorsement Endorsement Update
  • Management of Multifocal Lung Adenocarcinoma
  • Duration of Systemic Therapy for Stage IV Lung Cancer

Recently Published Guidelines

*Living Guideline